Skip to main content
. 2015 Jul 14;23(9):1444–1455. doi: 10.1038/mt.2015.112

Figure 5.

Figure 5

Effects of 4Mu + Cy + AdIL-12 combination on liver metastases of colorectal carcinoma. (a) Antimetastatic efficacy. BALB/c mice received intrahepatic inoculation of 5 × 105 CT26 cells (day 0). Then, mice were distributed in experimental groups and treated with saline (control group, n = 6; 4Mu (200 mg/kg/day, oral administration, o.a., during 3 weeks, from day 6, n = 6); Cy (50 mg/kg i.p., day 8) + AdIL-12 (109 TCID50 intravenously, i.v., day 9, n = 8) or 4Mu + Cy +AdIL-12 (n = 8). At day 21, animals were sacrificed and the volume of metastatic nodules was measured with caliper. Metastases complete regressions (%) were recorded for each group. (b) Survival. **P < 0.01 Kaplan Meier (4Mu+Cy+AdIL-12 versus Cy+AdIL-12), log rank test. Data are representative of three independent experiments. (c) Animal survival analysis in the metastatic model induced by the administration of CT26 cells into portal vein. Mice were distributed in experimental groups and treated with saline (control group, n = 8); 4Mu (200 mg/kg/day, oral administration, from day 7, n = 8); Cy (50 mg/kg i.p., day 8) + AdIL-12 (109 TCID50 intravenously, i.v., day 9 n = 6) or 4Mu + Cy +AdIL-12 (n = 8). ***P < 0.001 Kaplan Meier (4Mu+Cy+AdIL-12 versus Cy+AdIL-12), log rank test. Data are representative of two independent experiments.